All In Biotech

NDA 211109 · Tetraphase Pharms

Xerava

Eravacycline Dihydrochloride · Intravenous

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Mar 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Aug 27, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

0

0 Phase 3, 0 recruiting

FAERS reports

298

227 serious, 50 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 4, 2026.

XERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra‑abdominal infections in patients 18 years of age and older. ( 1.1 ) Limitations of Use XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI). ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 ) 1.1 Complicated Intra-abdominal Infections XERAVA is indicated for the treatment of complicated intra‑abdominal infections (cIAI) caused by susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens , Bacteroides species, and Parabacteroides distasonis in patients 18 years or older [see Microbiology ( 12.4 ) and Clinical Studies ( 14.1 )]. Limitations of Use XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI) [see Clinical Studies ( 14.2 )] . 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Mechanism: Eravacycline is an antibacterial drug [see Microbiology ( 12.4 )].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 27, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
2 products under this application
  • XERAVA · ERAVACYCLINE DIHYDROCHLORIDE EQ 50MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
  • XERAVA · ERAVACYCLINE DIHYDROCHLORIDE EQ 100MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Eravacycline Dihydrochloride" as an intervention, any sponsor and status, largest first.

All 0 trials

No registered drug trials name this ingredient.

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use98
  • drug ineffective33
  • blood fibrinogen decreased29
  • thrombocytopenia18
  • nausea15
  • product use in unapproved indication15
  • diarrhoea14
  • multiple organ dysfunction syndrome14
  • condition aggravated12
  • coagulopathy11
  • hypofibrinogenaemia11
  • lactic acidosis11

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201912
202010
202115
202229
202352
202441
202545
202694

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xerava (Eravacycline Di-Hydrochloride)

2024 spending

$690K

Beneficiaries

167

844 claims

Per beneficiary

$4,133

$2.48 per unit

View as table
YearSpending
2020$271,814
2021$402,034
2022$664,236
2023$788,061
2024$690,199

Part B: Xerava (Eravacycline Di-Hydrochloride) · HCPCS J0122

2024 spending

$146K

Beneficiaries

59

639 claims

Per beneficiary

$2,476

2024 ASP limit $1.17 per unit

View as table
YearSpending
2020$117,915
2021$83,663
2022$176,423
2023$108,177
2024$146,105

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Tetraphase Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.